SynOx Therapeutics
Robert Francomano is an experienced executive in the biopharmaceutical industry, having held the position of Chief Commercial Officer at multiple companies, including SynOx Therapeutics, SELLAS Life Sciences Group, Inc., and Stemline. In addition, Robert served as the Global Product Strategy Lead for Oncology at Baxalta and worked as a Strategic Consultant as a Senior Vice President in the Oncology sector. Robert's educational background includes Management Executive Education at the Massachusetts Institute of Technology and studies at The Wharton School.
This person is not in any teams
This person is not in any offices
SynOx Therapeutics
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.